Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nemtabrutinib, Bortezomib, and Rituximab for the Treatment of Waldenstrom's Macroglobulinemia (NEBULA)

NCT07464210 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT07464210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07464210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nemtabrutinib, Bortezomib, and Rituximab for the Treatment of Waldenstrom's Macroglobulinemia (NEBULA)
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
August 1, 2030
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia